MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression

Oncology Letters
Wei Zhang, Peng Luo

Abstract

Liver cancer is one of the most prevalent human tumors in the world. Despite recent advances regarding the understanding of the molecular basis of liver cancer and the introduction of novel chemotherapeutic approaches, liver cancer remains associated with a poor prognosis. Sirtuin 1 (SIRT1) was identified to be abnormally upregulated in liver cancer. Dysregulation of microRNAs (miRs/miRNAs) is associated with a variety of types of cancer, and miRNAs may also serve a role in tumorigenesis and progression. The present study demonstrated that following the selection of the cisplatin chemoresistant HepG2 cell line, miR-29c is downregulated using reverse transcription-quantitative polymerase chain reaction. Furthermore, overexpression of miR-29c in cisplatin-resistant cancer cells was demonstrated to inhibit tumor cell proliferation and to promote apoptosis in vitro and in vivo, as well as restoring cisplatin chemosensitivity by using a cell counting assay, colony formation assay, Annexin V-fluorescein isothocyanate/propidium iodide apoptosis analysis, terminal deoxynucleotidyl transferase dUTP nick end labeling and xenograft tumors in nude mice. Mechanistically, according to bioinformatics analysis and a luciferase assay, miR-29c m...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Feb 22, 2005·PLoS Biology·Julius BrenneckeStephen M Cohen
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kapil N Bhalla
Jun 10, 2005·Nature·S D HatfieldH Ruohola-Baker
Aug 17, 2005·Cancer Research·Marilena V IorioCarlo M Croce
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jordan M CumminsVictor E Velculescu
Dec 21, 2006·Cancer Research·Yuri PekarskyCarlo M Croce
Jul 10, 2007·Cancer Research·Kati P PorkkaTapio Visakorpi
Sep 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Muller FabbriCarlo M Croce
Sep 16, 2009·Human Pathology·Dolores López-TerradaBarbara B Knowles
Nov 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angela J ZiebarthCharles N Landen
Jan 23, 2013·Molecular Cancer Therapeutics·Simone PortmannDeborah Stroka
May 15, 2013·Journal of Hepatology·Yanxin ChangHongyang Wang
Oct 12, 2013·Genes & Development·Leonard Guarente
Nov 22, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xin YangLun-Xiu Qin
Mar 18, 2015·Molecular Medicine Reports·Peng LuoGang Li
May 1, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuting WuJun Li
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Aug 16, 2016·Genetics and Molecular Research : GMR·C W DongS Y Hu
Feb 18, 2017·Journal of Cellular and Molecular Medicine·Lin ChengHongxin Deng
Jun 7, 2017·CA: a Cancer Journal for Clinicians·Farhad IslamiAhmedin Jemal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.